Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus XR for Subclinical AMR in Kidney Transplant
NCT03380936Phase 1Terminated
- Sponsor
- University of Colorado Denver
- Start
- Jan 2018
- Primary completion
- Oct 2019
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in kidney transplant rejection comparing Envarsus XR Conversion with Standard of Care (2 arms). Primary endpoint: Change in Acute Inflammatory Histologic Parameters at 6 months. Started Jan 2018; status: terminated.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03380936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380936.